STOK STOKE THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, STOKE THERAPEUTICS INC reported revenue of $9.33M (down 32.5% from a year earlier), net income of −$61.6M and diluted EPS of −$0.93; over the last four quarters revenue was $27.6M and net income −$208M; for the fiscal year ended December 2025 revenue was $184M, up 404.5% on the year before.

STOK annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $184M, gross profit n/a, operating income −$20.6M, net income −$6.89M (margin -3.7%), EPS −$0.12
• Fiscal year ended Dec 2024: revenue $36.6M, gross profit n/a, operating income −$101M, net income −$89.0M (margin -243.4%), EPS −$1.65
• Fiscal year ended Dec 2023: revenue $8.78M, gross profit n/a, operating income −$115M, net income −$105M (margin -1192.5%), EPS −$2.38
• Fiscal year ended Dec 2022: revenue $12.4M, gross profit n/a, operating income −$104M, net income −$101M (margin -814.7%), EPS −$2.60
• Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$86.1M, net income −$85.8M (margin n/a), EPS −$2.34

STOK quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $9.33M (down 32.5% year over year), net income −$61.6M, EPS −$0.93
• Quarter ended Mar 31, 2026: revenue $6.23M (down 96.1% year over year), net income −$50.0M, EPS −$0.79
• Quarter ended Dec 31, 2025 (from the annual report): revenue $1.40M (down 93.8% year over year), net income −$57.9M, EPS −$0.97
• Quarter ended Sep 30, 2025: revenue $10.6M (up 117.2% year over year), net income −$38.3M, EPS −$0.65
• Quarter ended Jun 30, 2025: revenue $13.8M (up 186.0% year over year), net income −$23.5M, EPS −$0.40
• Quarter ended Mar 31, 2025: revenue $159M (up 3661.1% year over year), net income $113M, EPS $1.90
• Quarter ended Dec 31, 2024 (from the annual report): revenue $22.6M (up 707.4% year over year), net income −$10.5M, EPS −$0.15
• Quarter ended Sep 30, 2024: revenue $4.89M (up 47.9% year over year), net income −$26.4M, EPS −$0.47
• Quarter ended Jun 30, 2024: revenue $4.83M (up 294.7% year over year), net income −$25.7M, EPS −$0.46
• Quarter ended Mar 31, 2024: revenue $4.22M (down 18.2% year over year), net income −$26.4M, EPS −$0.57
• Quarter ended Dec 31, 2023 (from the annual report): revenue $2.80M (down 14.3% year over year), net income −$27.0M, EPS −$0.61
• Quarter ended Sep 30, 2023: revenue $3.31M (up 13.9% year over year), net income −$24.5M, EPS −$0.55
• Quarter ended Jun 30, 2023: revenue −$2.48M (down 176.8% year over year), net income −$30.7M, EPS −$0.69
• Quarter ended Mar 31, 2023: revenue $5.15M (up 71.7% year over year), net income −$22.5M, EPS −$0.53
• Quarter ended Dec 31, 2022 (from the annual report): revenue $3.27M, net income −$25.7M, EPS −$0.65
• Quarter ended Sep 30, 2022: revenue $2.91M, net income −$26.1M, EPS −$0.66
• Quarter ended Jun 30, 2022: revenue $3.23M, net income −$24.7M, EPS −$0.63
• Quarter ended Mar 31, 2022: revenue $3.00M, net income −$24.6M, EPS −$0.66
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$24.4M, EPS −$0.68
• Quarter ended Sep 30, 2021: revenue n/a, net income −$22.6M, EPS −$0.60

STOK cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $45.6M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$86.9M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$81.1M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$31.9M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$66.9M, share buybacks n/a

STOK balance sheet

• Jun 30, 2026: cash $110M, total assets $394M, total liabilities $48.4M, shareholders' equity $346M
• Mar 31, 2026: cash $156M, total assets $443M, total liabilities $48.4M, shareholders' equity $395M
• Dec 31, 2025: cash $84.2M, total assets $418M, total liabilities $66.0M, shareholders' equity $352M
• Sep 30, 2025: cash $83.4M, total assets $360M, total liabilities $52.2M, shareholders' equity $308M
• Jun 30, 2025: cash $101M, total assets $385M, total liabilities $49.6M, shareholders' equity $335M
• Mar 31, 2025: cash $275M, total assets $407M, total liabilities $56.8M, shareholders' equity $350M
• Dec 31, 2024: cash $128M, total assets $272M, total liabilities $42.5M, shareholders' equity $229M
• Sep 30, 2024: cash $150M, total assets $293M, total liabilities $61.2M, shareholders' equity $232M

What is STOK's revenue?

STOKE THERAPEUTICS INC reported $27.6M of revenue over its last four quarters, through June 30, 2026.

Is STOK profitable?

No. STOKE THERAPEUTICS INC lost $208M over the last four quarters.

What is STOK's EPS?

Diluted earnings per share over the last four quarters were −$3.34; −$0.93 in the latest quarter.

STOK ownership and insider trades · All stocks